MiR-610 Functions As a Tumor Suppressor in Oral Squamous Cell Carcinoma by Directly Targeting AGK
Overview
Pharmacology
Toxicology
Affiliations
Objective: MicroRNA-610 (miR-610) functions as a tumor suppressor in various types of cancers. However, whether miR-610 acted as a functional miRNA in oral squamous cell carcinoma (OSCC) is still largely unknown. The current study was designed to explore the expression pattern and function of miR-610 in OSCC and to investigate the possible molecular mechanisms.
Patients And Methods: Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) was performed to detect the expression of miR-610 in OSCC tissues and cells lines. The associations between miR-610 expression and clinicopathologic features and prognosis were analyzed. Proliferation, migration, and invasion capacities of OSCC cells were assessed after overexpressing miR-610. The regulation of acylglycerol kinase (AGK) by miR-610 was confirmed by Western blotting, Dual-Luciferase reporter assays and rescue experiments.
Results: We found that miR-610 expression was significantly down-regulated in both OSCC tissues and cell lines. Low miR-610 expression was associated with advanced T classification, TNM stage and poorer prognosis of OSCC patients. Functionally, the overexpression of miR-610 significantly suppressed OSCC cells proliferation, migration, invasion and EMT process. Mechanistically, AGK was confirmed to be the downstream target of miR-610 in OSCC cells. Furthermore, forced expression of AGK could rescue the inhibiting roles on cell proliferation and metastasis induced by miR-610 in OSCC cells.
Conclusions: Our findings highlight the important role of miR-610 in regulating OSCC progression by targeting AGK, indicating that miR-610 may represent a novel potential therapeutic target and prognostic marker for OSCC.
LncRNA C2orf27A Promotes Gastric Cancer by Sponging MiR-610 and Elevating NOX4 Expression.
Zhuang M, Guo X, Lin D, Lin N, Wang X, Chen F J Cancer. 2025; 16(5):1504-1518.
PMID: 39991587 PMC: 11843226. DOI: 10.7150/jca.100621.
Sun R, Liu Y, Sun Y, Zhou M, Wang Y, Shi B Acta Pharmacol Sin. 2024; 45(9):1937-1950.
PMID: 38750075 PMC: 11336244. DOI: 10.1038/s41401-024-01287-8.
Research progress and clinical application prospects of miRNAs in oral cancer.
Xing L, Feng Z, Nie H, Liu M, Liu Y, Zhang X Mol Biol Rep. 2022; 49(11):10653-10665.
PMID: 35725854 DOI: 10.1007/s11033-022-07604-w.
Long Y, Li C, Zhu B Bioengineered. 2022; 13(5):13055-13069.
PMID: 35635053 PMC: 9275858. DOI: 10.1080/21655979.2022.2074106.
Acylglycerol Kinase-Targeted Therapies in Oncology.
Chu B, Hong Z, Zheng X Front Cell Dev Biol. 2021; 9:659158.
PMID: 34368119 PMC: 8339474. DOI: 10.3389/fcell.2021.659158.